Astera Labs, Inc. (NASDAQ:ALAB) is one of the On May 6, 2026, Needham raised the firm’s price target on Astera Labs, Inc. (NASDAQ:ALAB) to $260 from $220 while maintaining a Buy rating.
The firm said the company delivered another significant beat-and-raise quarter, driven by continued growth across its Scorpio, Aries, and Taurus product families
Needham also noted that Astera Labs expects its optical portfolio to begin ramping in FY27, leveraging technology acquired through the aiXscale transaction. Roth Capital also raised its price target on Astera Labs, Inc. (NASDAQ:ALAB) to $275 from $225 while maintaining a Buy rating. The firm said the company posted another strong revenue beat and guidance increase, supported by ongoing PCIe retimer growth and increasing contributions from PCIe switch products.
Similarly, RBC Capital raised its price target on Astera Labs, Inc. (NASDAQ:ALAB) to $270 from $250 and maintained an Outperform rating. RBC said the quarter was driven by generative AI demand and continued new product ramps. The firm added that Astera Labs’ core PCIe retimer business continues to benefit from the transition to Gen6, while Scorpio-P switch revenue exceeded 20% of total sales during the quarter, with two additional customer ramps expected later this year.